Articles On Orthocell (ASX:OCC)

The regenerative medicine company focused on advancing its CelGro® and Ortho-ATI® pipelines during FY21, ending the period with more than $16 million in the bank.

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Local markets have made a strong start to the week, with the ASX200 closing 1.34% higher on Monday as some major M&A activity stole the headlines. Gains were led by the tech sector, as Afterpay (ASX:APT) showed its weight by dragging th...

The findings represent a substantial advance in the ex vivo fabrication of implantable lymphatic grafts and their use in novel surgical treatments for patients suffering from lymphedema.

The biggest winner in health stocks today was Hydrix (ASX:HYD) – up 9.68% off the back of news that Angel Medical Systems had completed its first commercial implantation in the US of the Guardian device – a cardiac detection monitor and pat...

The ASX-lister tabled data from a key CelGro® nerve regeneration trial and worked towards getting its Striate+ product to the US market over the June quarter, with data from a rotator cuff trial using the Ortho-API® product anticipated this...

The ASX-lister tabled data from a key CelGro® nerve regeneration trial and worked towards getting its Striate+ product to the US market over the June quarter, with data from a rotator cuff trial using the Ortho-ATI® product anticipated this...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Summary Kirkland (ASX:KLA) reports record production in second quarter 2021 Finbar (ASX:FRI) rises after forecasting 18% jump in FY net profit Pearl Global (ASX:PG1) climbs on supply deal with Alex Fraser The S&P/ASX200 closed...

The company believes SMT is the ideal partner for the Australian market, with its established relationships with oral surgeons and a successful track record driving market entry of high-quality products.

Shares in Perth-based regenerative medicine company Orthocell are climbing on news it has appointed an Australian distributor for its product for bone and soft tissue repair.

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Australian regenerative medicine company Orthocell (ASX:OCC) has announced the first interim data of all patients in the CelGro nerve regeneration trial at 12 months post-treatment.

Twelve months on from Orthocell’s CelGro® nerve regeneration trial, a data readout has indicated more than three-quarters of all nerve repairs conducted during the clinical study resulted in functional recovery.

The Orthocell Ltd (ASX: OCC) share price is gaining in morning trade, up 3.3%. Below we take a look at the regenerative medicine company’s latest clinical update. What did Orthocell report? Orthocell’s share price is gaining after the comp...

Regenerative medicine company Orthocell (ASX:OCC) has announced Chinese and New Zealand patents have been granted for its CelGro collagen medical device platform for soft tissue regeneration applications.

Summary Commonwealth Bank (ASX:CBA) sets new high, adds nearly A$7 billion in value over 3 weeks Orthocell (ASX:OCC) gets patents for suture-less repair of soft tissue AF Legal Group (ASX:AFL) completes Watts McCray acquisition...

Summary The ASX 200 breached 7,400 level for the first time to hit a fresh high of 7,406.20. The index closed 6.70 points higher at 7,386.20 ahead of the US Fed meeting scheduled tonight. The widely anticipated US Fed policy statement...

The patents cover the method of using CelGro® to repair a defect in soft tissue, such as tendons, ligaments and nerves, avoiding the use of damaging sutures.

The Orthocell Ltd (ASX: OCC) share price is climbing today. At the time of writing, it’s at 57.5 cents, up by 1.77%, settling back after jumping 4% in early trading. Let’s have a look at the latest announcement from the regenerative medici...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

A recent article published in the Advance Science magazine discussed research by Monash University that uncovered a new technique to alter the shape of individual stem cells, which could potentially speed up recovery times for bone replacem...

Regenerative medicine company Orthocell (ASX:OCC) has announced Chinese and Hong Kong patents have been granted for its novel CelGro collagen rope device, to augment the surgical repair of anterior cruciate ligament injuries.

China and Hong Kong have granted patents to the product, which is used to augment ligament repair surgeries.

China and Hong Kong have granted patents to the product, which is used to augment ligament repair surgeries.

Orthocell is well-positioned to establish CelGro® as the best-in-class membrane for bone and soft tissue repair and to realise multiple commercial partnering opportunities.

Regenerative medicine company Orthocell (ASX:OCC) has announced what it describes as positive results from the US animal pilot study of its CelGro in nerve regeneration compared to the current market-leading device.

Summary Regenerative medicine player Orthocell has announced positive results from the US 510(k) animal pilot study of CelGro®. AnteoTech has obtained firm commitments to raise AU$12M to accelerate its test product pipeline. Althou...

The breakthrough results position CelGro® as the potential market leader in nerve regeneration and restoration of voluntary muscle control in patients with tetraplegia or paralysed upper limbs with a strategic evaluation of medical device U...

The Orthocell Ltd (ASX: OCC) share price is rising today following news of a successful pilot animal study. The company states that as a result of the study, it’s seeking to fast-track US approval for its CelGro product. The Orthocell shar...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Regenerative medicine company Orthocell (ASX:OCC) has announced it has received notification from the Australian Department of Health that its CelGro Dental has been included on the Prostheses List.

Source:Phongphan ,Shutterstock ASX 200 has held its gains in the afternoon today. Australian bond yields are tracking lower today, while information technology sector is also lower. Australian markets are trading higher today. Most of th...

The Orthocell Ltd (ASX: OCC) share price is edging higher today following the inclusion of CelGro Dental on the Australian Prostheses List. When news broke out, the regenerative medicine company’s shares raced higher to 54 cents, before ea...

Source: Voronin76,Shutterstock Summary World-leading regenerative medicine company Orthocell revealed that CelGro® Dental was included on the Australian Prostheses List. Additional antiviral testing proved that Starpharma’s antiviral...

The prostheses list defines the minimum value of benefit private insurers pay for CelGro® Dental used in approved dental bone and soft tissue repair procedures.

Source: Guschenkova, Shutterstock Summary Amid the detrimental impact of the ongoing pandemic, the healthcare sector has continued to witness new heights. Penny stocks are grabbing attention from market participants as they are low-pr...

Australian regenerative medicine company Orthocell (ASX:OCC) has been granted a new US method of use patent for its CelGro product.

Summary World-leading regenerative medicine player Orthocell Limited has obtained US patent for CelGro®. The patent also complements market authorisation of Striate+, the first CelGro® product. CelGro® offers its benefits in the field...

Summary ASX shares have been on an upward swing on Monday. The benchmark index rose sharply since the Morning and is up nearly 1%.  Gold spot, copper, and iron ore prices were seen lower, while oil and coal prices were higher.  ASX...

The Orthocell Ltd (ASX: OCC) share price has had a mixed day of trading so far after the company announced a new United States patent for its flagship product. After tracking as high as 58 cents this morning, shares in the regenerative med...

Patents for CelGro® have previously been granted in the US, Canada, Europe, China, Japan, Singapore, Australia and New Zealand, and the new US divisional patent further protects and strengthens the IP position by providing greater layers of...